Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

LRMR

NASDAQ

Larimar Therapeutics (LRMR)

2.70 USD −1.46% vs prior close Nov 12, 2026
Larimar Therapeutics, Inc. price graph
26 sessions
3.0 1.5 8 Oct 12 Nov

The line runs 2.70 USD on 8 October through 2.70 USD on 12 November, on a scale from 1.5 to 3.0. Days the market did not trade hold the previous close, flat.

Market cap
282.5M USD
52-week range
1.99 USD – 6 USD
Avg volume
165.9K

as of Nov 12, 2026

Have Larimar Therapeutics (LRMR) insiders bought or sold shares recently?

In the 90 days to 22 Nov 2026, Larimar Therapeutics insiders reported 9 open-market purchases and no sales (SEC Form 4).

Form 4, 90 days to 22 Nov 2026, newest reported trade 16 Nov 2026

9buys
0sells
$402Knet bought
1other filings
Have Larimar Therapeutics (LRMR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
16 Nov 2026SHERMAN JEFFREY WDirectorBuy3,28910K USD
16 Nov 2026Clayton RussellChief Medical OfficerBuy3,32210K USD
12 Nov 2026Hamilton Thomas EdwardDirectorBuy70,000187K USD
11 Nov 2026BEN-MAIMON CAROLEPresident and CEOBuy18,05050K USD
11 Nov 2026Celano MichaelChief Financial OfficerBuy18,46050K USD
11 Nov 2026Harlow John B. Jr.President and COOBuy17,80050K USD
11 Nov 2026Shankar GopiChief Development OfficerBuy5,00014K USD
11 Nov 2026Truitt JosephDirectorBuy3,50010K USD
11 Nov 2026THOMAS FRANK EDirectorBuy8,00022K USD
Bought9 open-market purchases147,421$402K
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Larimar Therapeutics (LRMR) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
29 Sep 2026Harlow John B. Jr.President and COOAward50,000

Which funds hold Larimar Therapeutics (LRMR)?

7 of the 45 institutional funds we track reported a Larimar Therapeutics position for the quarter ended 30 Sep 2026 — a combined 22.9M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Larimar Therapeutics (LRMR)?
FundPositionSharesValueShares q/q
AQR Capital ManagementHeld (±25%)2,240,6237.2M USD−5.5%
Marshall WaceHeld (±25%)2,195,9547.0M USD+9.1%
Millennium ManagementAdded1,669,0475.3M USD+25.2%
D. E. Shaw & Co.New position568,5981.8M USD
Two Sigma InvestmentsHeld (±25%)236,133754K USD
Renaissance TechnologiesTrimmed184,043588K USD−38.1%
Citadel AdvisorsTrimmed66,377212K USD−95.4%
Balyasny Asset ManagementExited
Man GroupExited
Point72 Asset ManagementExited

What has been filed or recorded for Larimar Therapeutics (LRMR)?

The filings we hold for Larimar Therapeutics, newest first: 7 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 3 reported financial figures, the latest dated 26 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Larimar Therapeutics (LRMR)?
And
26 Oct 2026Fails to deliverShares failed to deliver435 shares1K USD notional · <0.001% of shares out
23 Oct 2026Fails to deliverShares failed to deliver431 shares978 USD notional · <0.001% of shares out
20 Oct 2026Fails to deliverShares failed to deliver105 shares223 USD notional · <0.001% of shares out
16 Oct 2026Fails to deliverShares failed to deliver443 shares882 USD notional · <0.001% of shares out
14 Oct 2026Fails to deliverShares failed to deliver49,053 shares106K USD notional · 0.047% of shares out
13 Oct 2026Fails to deliverShares failed to deliver8,670 shares22K USD notional · 0.008% of shares out
09 Oct 2026Fails to deliverShares failed to deliver699 shares2K USD notional · 0.001% of shares out
30 Sep 2026FinancialsTotal assets140.5M USDat period end
30 Sep 2026FinancialsTotal equity101.5M USDat period end
31 Dec 2025FinancialsNet income−165.7M USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.61 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.41 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.46 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.32 USD
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.24 USD
30 Jun 2024Quarterly earningsQ2 2024 reportedEPS −0.34 USD
31 Mar 2024Quarterly earningsQ1 2024 reportedEPS −0.27 USD
31 Dec 2023Annual reportFY 2023 reportedEPS −0.84 USD

What do people ask about Larimar Therapeutics (LRMR)?

From live data
What did Larimar Therapeutics shares close at?2.70

Larimar Therapeutics closed at 2.70 USD on 12 Nov 2026, down 1.46% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Larimar Therapeutics’ market cap?282.5M

Larimar Therapeutics is worth 282.5M USD by market value as of 12 Nov 2026, which is the share price times the shares on issue from its SEC filings.

Have Larimar Therapeutics insiders bought or sold shares recently?9 purchases

In the 90 days to 22 Nov 2026, Larimar Therapeutics insiders reported 9 open-market purchases and no sales (SEC Form 4). A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Larimar Therapeutics?7 of 45

7 of the 45 funds we track reported a Larimar Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Marshall Wace and Millennium Management. See Funds

When did Larimar Therapeutics last report earnings?−0.61

Larimar Therapeutics last reported earnings on 30 Sep 2025 for Q3 2025, with EPS of −0.61 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words